Engineered immune cells take on lupus in early trial
NCT ID NCT07339332
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study is testing a new type of immunotherapy called universal CAR-T cells in 12 people with moderate to severe lupus that hasn't responded to standard treatments. The cells are designed to target and destroy faulty immune cells driving the disease. The main goals are to check safety and find the right dose, while also seeing if it can improve lupus symptoms.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
universal CD19/20 CAR-T cells (CT1195E)
What this could lead to
If it works, this could point toward a new treatment option for people with hard-to-treat lupus, potentially reducing disease activity without lifelong medication.
What could go wrong
This is a very early, small trial (12 people) focused on safety. CAR-T therapy can cause severe side effects like cytokine release syndrome, and it is unknown if it will work for lupus or how long effects might last.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Wuhan Union Hospita
RECRUITINGWuhan, Hubei, 430000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••